Introduction
Peritoneal dissemination is a leading cause of death from gastrointestinal cancer; there is no effective treatment for peritoneal carcinomatosis. About 40% of patients with advanced gastric cancer died of this type of metastasis [1] . Considerable efforts have been made to prevent peritoneal recurrence, but large randomized trials have failed to demonstrate the efficacy of prevention. One of the major reasons for the pessimistic results of clinical trials lies in the poor understanding of the mechanisms of the formation of peritoneal dissemination.
At present, cancer metastasis is considered to be formed through multi-step processes by the activation of metastasis-related genes [2] . Peritoneal dissemination is also formed through several steps [2] : (1) detachment of cancer cells from the primary tumor, (2) attachment to distant peritoneum, (3) invasion into subperitoneal space, and (4) proliferation with vascular neogenesis. The origin of peritoneal carcinoamtosis in gastric cancer is considered to be intraperitoneal free cancer cells, exfoliated from the serosal surface of the primary tumor. In gastric cancer, intraperitoneal free cancer cells can be detected by peritoneal wash cytology in 40%-60% of patients with stage III or IV disease [4, 5] .
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However, the identity of the molecules that are associated with the process of cancer cell invasion into the submesothelial tissue remains unclear. Recent advances in molecular biology showed that matrix-degrading enzymes, including matrix metalloproteinases (MMPs) and serine proteases, were involved in tumor invasion.
Regarding MMPs, more than 17 subfamilies have been identified. Among them, MMP-7 is known to be expressed by the glandular epithelium [8] and by cancer cells [9, 10] , and other metalloproteinases are expressed not only by the stromal component [10] but also by the cancer cells. MMP-7 can degrade a wide range of substrates, including proteoglycans, fibronectin, gelatin, and casein. MMP-7 has a stronger enzymatic activity than any other members of the MMP family [11, 12] . In addition, MMP-7 activates other proMMPs such as proMMP-1, -3, -8, and -9 [13, 14] . Consequently, MMP-7 can cleave almost all kinds of stromal elements. ProMMP-7 is activated by 4-aminophenylmercuric acetate (APMA), trypsin, and MMP-3 following the stepwise mechanisms proposed for other proMMPs [15] .
We report here the close relationship between MMP-7 expression and peritoneal metastasis in gastric cancer. To the best of our knowledge, there has been no article published previously on this relationship.
Subjects, materials, and methods

Cell lines
Seven gastric cancer cell lines (KATO-III, KKLS, MKN-45, MKN-28, TMK-1, NKPS, and NUGC-3) and a cell line of fibroblasts (KMST-6) were cultured in RPMI-1640 medium with 10% fetal calf serum (GIBCO BRL, Gaithersburg, MD, USA).
Patients and tumor samples
One hundred and thirty-six patients with primary gastric cancer diagnosed and treated at the Second Department of Surgery, Kanazawa University Hospital, between 1990 and 1997, were entered into the study. All the patients underwent gastrectomy with lymph node dissection. Immediately after resection of the primary tumor, samples, about 5-mm in diameter, were taken from 53 primary tumors, each adjacent normal mucosa, and 6 metastatic tumors on the peritoneal surface, and these samples were stored at Ϫ80°C. In addition, small pieces of tissue, about 5-to 8-mm in diameter, were sampled from the 136 primary tumors and 14 peritoneal metastases, fixed in acetone at Ϫ20°C overnight, and prepared to make paraffin-embedded blocks by the AMeX method [17] . All the resected primary tumors and regional lymph nodes were histologically examined by H&E staining, according to the general rules of the Japanese classification of gastric cancer [16] .
Antibodies and immunohistochemistry
Immunohistochemistry was done as described previously [6, 7] . Deparaffinized sections were incubated overnight at 4°C with anti-MMP-7 antibody (Fuji Pharmaceutical, Takaoka, Japan) diluted 1 : 100 in phosphate-buffered saline (PBS). This monoclonal antibody was developed using a synthetic peptide corresponding to the amino acid sequence of the COOH-terminal peptide of human MMP-7 (residues 253-267) [9] . Next, the slides were incubated with biotinylated goat antimouse IgG for 20 min (LSAB kit; Dako, Copenhagen, Denmark) and then with premixed Avidin-Biotin complex (ABC) (Dako) reagent for 20 min. Immunostaining was done with diaminobenzidine (Dako) solution with hydrogen peroxide for 1 min. Negative controls were done in all cases by omitting the first antibody. Only cases in which at least 20% of the tumor cells were immunoreactive were scored as positive.
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR analysis was done according to Ng et al. [19] and Conboy et al. [20] , modifications. With Briefly, total RNAs were extracted from primary gastric cancer, normal gastric mucosa, the cell line of fibroblasts (KMST6), human mesothelial cells, and the seven gastric cancer cell lines, using Isogen (Nippon Gene, Tokyo, Japan) [18] . Human mesothelial cells were isolated from human greater omentum, as we have already reported [21] . The prepared RNA was mixed with oligo-dT primer and was reverse-transcribed with avian mylo cytic leukemia virus (AMV) reverse transcriptase (Life Sciences, St. Petersburg, Fl, USA), followed by PCR amplification (Perkin-Elmer Cetus, Norwalk, CT, USA) with specific primers (Table 1) . PCR amplifcation was done for 1.5 min at 94°C, 2 min at 48°C, and 2 min at 72°C for three cycles, then with 25 cycles of 40 s at 94°C, 1.5 min at 48°C, and 1.3 min at 72°C. The PCR products were electrophoresed on 2% agarose gels and transferred to a nylon membrane filter. The transferred products were hybridized overnight to a 32 P-end-labeled probe specific for the target cDNA fragment ( Table 1 ).
The autoradiogram was exposed for 4-5 h with two intensifying screens at Ϫ80°C. Specific primers for the MMP-7 gene, -actin gene, and transferrin receptor (TFR) gene are shown in Table 1 [19, 20] . 
Data presentation and statistical analysis
Results
MMP-7 expression in gastric cancer cell lines, fibroblasts, and primary gastric cancer
MMP-7 mRNA was expressed in MKN-45, NUGC-3, KATO-III, NKPS, and MKN-28, but TMK-1 and KKLS did not express MMP-7 mRNA (Fig. 1) . KMST6, which is an immortalized cell line of fibroblasts, did not express MMP-7 mRNA (Fig. 1) .
In the clinical specimens, MMP-7 mRNA was mainly expressed in primary tumors (Fig. 2) . MMP-7 mRNA was detected in 28 (53%) of 53 primary gastric cancers, but not in normal gastric mucosa.
Tissue localization and expression of MMP-7 in gastric cancer and peritoneal dissemination
As shown in Fig. 3 , immunohistochemical study showed MMP-7 expression on the cytoplasm or cell membrane of gastric cancers, but not in the normal gastric mucosa or stromal tissue. MMP-7 immunoreactivity was expressed in 70 (51%) of the 136 primary gastric cancers. 
Relationship between clinicopathological parameters and MMP-7 expression
MMP-7 mRNA expression in primary tumors had a significant relationship with positive serosal involvement (Table 2) . Peritoneal dissemination was found in 2 (8%) of 25 MMP-7 mRNA-negative tumors, but 9 (32%) of 28 MMP-7 mRNA-positive tumors had peritoneal dissemination (P Ͻ 0.05). Tissue status of MMP-7 protein expression was significantly associated with lymph node metastasis, serosal involvement, peritoneal dissemination, and lymphatic invasion (Table 3 ). In addition, MMP-7 immunoreactivity was expressed in a significantly higher proportion of poorly differentiated adenocarcinomas compared with that in differentiated adenocarcinomas (Table 3 ). Infiltrating type of cancer tended to overexpress MMP-7 more than did localized tumors, and the proportion of MMP-7 overexpression in early gastric cancer (21%; 7/33) was significantly lower than that in advanced gastric cancer (61%; 63/ 103) (P Ͻ 0.05).
Survival of patients in terms of MMP-7 tissue status, and recurrence mode after operation
As shown in Fig. 4 , the survival rate was lower for patients with gastric cancer with positive MMP-7 status than for those with MMP-7-negative status. (Table 4 ). This was significantly higher than the proportion (8%; 5/66) in patients with MMP-7-negative tumors. 
MMP-7 expression in peritoneal dissemination
MMP-7 immunoreactivity was found in specimens from peritoneal dissemination (Fig. 5) , with a positive incidence of 93% (13/14) . One tumor that was negative for MMP-7 immunoreactivity was pseudomyxoma peritonei from gastric cancer. [22, 23] , are also involved in the progression of gastric cancer. Among these matrixdegrading enzymes, MMP-7 is unique, in that it is expressed by tumor cells themselves rather than by the stromal cells [8] . By the in-situ hybridization technique, Yamashita et al. [24] reported that MMP-7 mRNA signals were exclusively found in the cytoplasm of gastric cancer cells. In this present study, KMST-6, a fibroblast cell line, and normal gastric mucosa and mesothelial cells did not express MMP-7 mRNA.
These results indicate that MMP-7 is mainly produced by gastric cancer cells. Accordingly, MMP-7-producing cancer cells have a high matrix-degrading activity in the pericellular space, making them highly invasive.
In the clinical specimens, primary tumros with MMP-7 overexpression were significantly more likely to show positive serosal involvement, lymph node metastasis, and peritoneal dissemination than did the specimens Figure 6 shows the MMP-7 mRNA expression in peritoneal disseminations. Although mesothelial cells did not express MMP-7, bands compatible with MMP-7 mRNA were found in all the samples obtained from peritoneal disseminations.
We did a logistic regression analysis to identify the independent risk factors for peritoneal dissemination. As shown in Table 5 , MMP-7 tissue status emerged as an independent risk factor for peritoneal dissemination.
Discussion
As shown in the logistic regression analysis, MMP-7 tissue status in gastric cancer was an independent with MMP-7 negative tumors. Furthermore, MMP-7 overexpression in poorly differentiated adenocarcinoma and the macroscopically infiltrating type was significantly more frequent than that in differentiated adenocarcinoma and the localized type.
The phenotypes of poorly differentiated adenocarcinoma or macroscopically infiltrating tumor are well known as tumors that tend to develop peritoneal recurrence [1] . Poorly differentiated adenocarcinomas tend to grow in an infiltrating type of tumor growth pattern and to exfoliate easily from the serosal surface, because of the loss of cell-to-cell adhesion due to an abnormality of the E-cadherin gene [25] .
Accordingly, simultaneous expression of MMP-7 and down-regulation of E-cadherin expression may render gastric cancer cells more invasive and metastatic. As a result, these cancer cells are prone to exfoliate from the serosal surface and to become intraperitoneal free cancer cells.
We previously reported a significant role of integrins α2 and α3 in the attachment of intraperitoneal free cancer cells on the peritoneal surface [6] . After such attachment, cancer cells must invade the subperitoneal tissue and move to the perivascular space to get enough nutrition and oxygen from submesothelial blood capillaries [26] . If cancer cells have no ability to invade the subperitoneal tissue, almost all the cells may die off on the peritoneal surface. To accomplish the invasion process smoothly, the production of matrix-degrading enzymes in the pericellular space of the cancer cells is essential. In the early stage of peritoneal dissemination, however, inflammatory reactions may be rare, and cancer cells cannot invade the subperitoneal tissue by using matrix-degrading enzymes, such as MMP-2 and MMP-9, which are produced by fibroblasts or inflammatory cells.
Accordingly, MMP-7, which is exclusively produced by the cancer cells themselves, must have an important role in the completion of this process. Interestingly, this present study demonstrated that MMP-7 mRNA was detected in all specimens of peritoneal dissemination. In addition, logistic regression analysis demonstrated that MMP-7 tissue status was an independent risk factor for peritoneal dissemination.
These results suggest that the clonal selection of cancer cells with MMP-7 overexpression may occur during the invasion of intraperitoneal free cancer cells from the peritoneal surface into the subperitoneal tissue.
Furthermore, these results suggest that MMP-7 has a large role in the establishment of peritoneal dissemination, and that MMP-7 is a reliable predictor of peritoneal recurrence after curative resection of gastric cancer. Accordingly, MMP-7 may be a highly suitable molecular target for gene therapy for peritoneal carcinomatosis. We are now trying to treat experimental peritoneal carcinomatosis with antisense oligonucleotides against MMP-7 mRNA.
